{ "run": { "id": "cmnr15d8d06qsp658tbyv4abx", "region": "US", "assetId": "cmnr15d7g06qmp658rb0325fx", "ticker": "UHS", "snapshotId": "cmnr15d7r06qqp658rv74s3rq", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:22:00.625Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr15d7r06qqp658rv74s3rq", "assetId": "cmnr15d7g06qmp658rb0325fx", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 183.47, "price": 186.76, "dayLow": 182.29, "volume": 561886, "dayHigh": 187.625, "currency": "USD", "prevClose": 180.61, "week52Low": 152.3278, "week52High": 246.325 }, "fundamentals": { "pe": 9.30913748932536, "beta": 0.816306996103801, "epsTTM": 23.42, "fcfTTM": 809782000, "growth": { "epsYoy": 0.3648018648018649, "revenueYoy": 0.09710009549571691 }, "sector": "Services-General Medical & Surgical Hospitals, NEC", "margins": { "net": 0.08573628913938629, "gross": null, "operating": 0.1148306729654522 }, "website": "http://uhs.com", "industry": null, "pegRatio": 0.255183385490133, "ebitdaTTM": 2734472000, "forwardPe": 9.26955782312925, "marketCap": 9700000000, "totalCash": 137797000, "totalDebt": 5500709000, "debtEquity": 0.756028896922837, "quickRatio": 0.8458544740540579, "revenueTTM": 17364829000, "companyName": "UNIVERSAL HEALTH SERVICES INC", "priceToBook": 1.12808745480954, "currentRatio": 1.051955163614285, "dividendYield": 0.00370078347000004, "returnOnAssets": 0.09588066869089111, "returnOnEquity": 0.204623221774344, "analystOpinions": null, "businessSummary": "Universal Health Services, Inc. (UHS) is an American Fortune 500 company that provides hospital and healthcare services, based in King of Prussia, Pennsylvania. In 2024, UHS reported total revenues of $15.8 billion.", "enterpriseValue": 19224841620, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 101500, "sharesOutstanding": null, "enterpriseToEbitda": 7.030549817295624, "analystTargetMedian": null, "enterpriseToRevenue": 1.107113788451358, "operatingCashflowTTM": 1864397000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:22:00.616Z" }, "results": [ { "id": "cmnr15d8h06qup658tv72xj63", "runId": "cmnr15d8d06qsp658tbyv4abx", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"UHS\",\"currency\":\"USD\",\"current_price\":186.76,\"target_price_6m\":205,\"target_price_12m\":222,\"recommendation\":\"BUY\",\"confidence\":0.68,\"thesis_bullets\":[\"PE of 9.3x with 36% EPS growth signals meaningful undervaluation\",\"FCF yield ~8.4% supports shareholder returns and deleveraging capacity\",\"Revenue growing ~10% YoY with operating margin expansion potential\",\"Stock 24% below 52-week high creates attractive entry point\",\"EV/EBITDA of 7x is below historical hospital-sector median of 8-9x\"],\"key_drivers\":[{\"driver\":\"Behavioral health volume growth and reimbursement trends\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Acute care same-store revenue per adjusted admission gains\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Labor cost normalization post-pandemic premium staffing\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Medicaid redetermination headwinds on payer mix\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Elevated leverage ($5.5B debt) limits financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Potential hospital-sector reimbursement cuts in federal budget\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Strong FCF generation supporting buybacks and dividends\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Macro slowdown risk reducing elective procedure volumes\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Federal or state Medicaid/Medicare reimbursement rate cuts\",\"Wage inflation re-acceleration compressing operating margins\",\"Rising interest expense on $5.5B debt load in higher-rate environment\",\"Regulatory or compliance risk inherent in behavioral health operations\",\"Cyclical volume softness if consumer economy weakens materially\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.12,\"wacc\":0.09,\"terminal_multiple\":8.5},\"scenarios\":{\"bear\":{\"target_price\":155,\"prob\":0.2,\"notes\":\"Reimbursement cuts and margin compression push PE toward 7x on flat EPS.\"},\"base\":{\"target_price\":222,\"prob\":0.55,\"notes\":\"Moderate EPS growth to ~$25 with PE re-rating toward 9.5-10x.\"},\"bull\":{\"target_price\":265,\"prob\":0.25,\"notes\":\"Continued strong growth, margin expansion, PE re-rates to ~11x on ~$24+ EPS.\"}},\"method_notes\":\"Earnings-power valuation anchored on TTM EPS of $23.42, applying forward PE range 9.5-10x for base case reflecting sector discount and growth trajectory. Cross-checked with EV/EBITDA (7x vs 8-9x peer median) and FCF yield (8.4%). 12M target of $222 implies ~19% upside, supporting BUY. Confidence moderate given macro and reimbursement uncertainty. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ai-equity-research-v1", "risks": [ "Federal or state Medicaid/Medicare reimbursement rate cuts", "Wage inflation re-acceleration compressing operating margins", "Rising interest expense on $5.5B debt load in higher-rate environment", "Regulatory or compliance risk inherent in behavioral health operations", "Cyclical volume softness if consumer economy weakens materially" ], "ticker": "UHS", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Moderate EPS growth to ~$25 with PE re-rating toward 9.5-10x.", "target_price": 222 }, "bear": { "prob": 0.2, "notes": "Reimbursement cuts and margin compression push PE toward 7x on flat EPS.", "target_price": 155 }, "bull": { "prob": 0.25, "notes": "Continued strong growth, margin expansion, PE re-rates to ~11x on ~$24+ EPS.", "target_price": 265 } }, "confidence": 0.68, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.06, "terminal_multiple": 8.5, "ebit_margin_target": 0.12 }, "key_drivers": [ { "driver": "Behavioral health volume growth and reimbursement trends", "impact": "HIGH", "direction": "POS" }, { "driver": "Acute care same-store revenue per adjusted admission gains", "impact": "HIGH", "direction": "POS" }, { "driver": "Labor cost normalization post-pandemic premium staffing", "impact": "MED", "direction": "POS" }, { "driver": "Medicaid redetermination headwinds on payer mix", "impact": "MED", "direction": "NEG" }, { "driver": "Elevated leverage ($5.5B debt) limits financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Potential hospital-sector reimbursement cuts in federal budget", "impact": "HIGH", "direction": "NEG" }, { "driver": "Strong FCF generation supporting buybacks and dividends", "impact": "MED", "direction": "POS" }, { "driver": "Macro slowdown risk reducing elective procedure volumes", "impact": "MED", "direction": "NEG" } ], "method_notes": "Earnings-power valuation anchored on TTM EPS of $23.42, applying forward PE range 9.5-10x for base case reflecting sector discount and growth trajectory. Cross-checked with EV/EBITDA (7x vs 8-9x peer median) and FCF yield (8.4%). 12M target of $222 implies ~19% upside, supporting BUY. Confidence moderate given macro and reimbursement uncertainty. Not investment advice.", "current_price": 186.76, "recommendation": "BUY", "thesis_bullets": [ "PE of 9.3x with 36% EPS growth signals meaningful undervaluation", "FCF yield ~8.4% supports shareholder returns and deleveraging capacity", "Revenue growing ~10% YoY with operating margin expansion potential", "Stock 24% below 52-week high creates attractive entry point", "EV/EBITDA of 7x is below historical hospital-sector median of 8-9x" ], "target_price_6m": 205, "target_price_12m": 222 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 35857, "createdAt": "2026-04-09T05:22:00.625Z", "usage": { "inputTokens": 3565, "outputTokens": 1681, "costUsd": 0.05985 } }, { "id": "cmnr15d8h06qxp658gztn7e94", "runId": "cmnr15d8d06qsp658tbyv4abx", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"UHS\",\n \"currency\": \"USD\",\n \"current_price\": 186.76,\n \"target_price_6m\": 220.0,\n \"target_price_12m\": 260.0,\n \"recommendation\": \"STRONG_BUY\",\n \"confidence\": 0.78,\n \"thesis_bullets\": [\n \"Strong historical EPS growth at 36.5% year-over-year.\",\n \"Low PEG ratio of 0.255 indicates potential undervaluation.\",\n \"Stable revenue growth in resilient healthcare sector.\",\n \"Opportunity for margin expansion with operational improvements.\",\n \"Balanced by regulatory risks and moderate debt levels.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"EPS Growth Trajectory\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Revenue Growth Consistency\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Operating Margin Potential\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt and Interest Costs\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Healthcare Regulatory Changes\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Market Multiple Re-rating\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Labor Cost Inflation\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Patient Volume Stability\", \"impact\": \"HIGH\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Adverse changes in Medicare/Medicaid reimbursement rates.\",\n \"Increased competition from other hospital operators.\",\n \"Rising wages and supply costs pressuring margins.\",\n \"Economic downturn reducing elective procedure volumes.\",\n \"High debt levels affecting financial flexibility.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.09,\n \"ebit_margin_target\": 0.12,\n \"wacc\": 0.08,\n \"terminal_multiple\": 8.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 180.0, \"prob\": 0.2, \"notes\": \"Regulatory headwinds and slower growth compress multiples.\" },\n \"base\": { \"target_price\": 260.0, \"prob\": 0.6, \"notes\": \"Steady execution with margin improvement drives valuation.\" },\n \"bull\": { \"target_price\": 320.0, \"prob\": 0.2, \"notes\": \"Accelerated growth and multiple expansion lead to outperformance.\" }\n },\n \"method_notes\": \"Valuation based on earnings growth and EV/EBITDA multiples, with 12M target implying 39% upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Analyst", "risks": [ "Adverse changes in Medicare/Medicaid reimbursement rates.", "Increased competition from other hospital operators.", "Rising wages and supply costs pressuring margins.", "Economic downturn reducing elective procedure volumes.", "High debt levels affecting financial flexibility." ], "ticker": "UHS", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution with margin improvement drives valuation.", "target_price": 260 }, "bear": { "prob": 0.2, "notes": "Regulatory headwinds and slower growth compress multiples.", "target_price": 180 }, "bull": { "prob": 0.2, "notes": "Accelerated growth and multiple expansion lead to outperformance.", "target_price": 320 } }, "confidence": 0.78, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.09, "terminal_multiple": 8, "ebit_margin_target": 0.12 }, "key_drivers": [ { "driver": "EPS Growth Trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue Growth Consistency", "impact": "MED", "direction": "POS" }, { "driver": "Operating Margin Potential", "impact": "MED", "direction": "POS" }, { "driver": "Debt and Interest Costs", "impact": "MED", "direction": "NEG" }, { "driver": "Healthcare Regulatory Changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Market Multiple Re-rating", "impact": "HIGH", "direction": "POS" }, { "driver": "Labor Cost Inflation", "impact": "MED", "direction": "NEG" }, { "driver": "Patient Volume Stability", "impact": "HIGH", "direction": "POS" } ], "method_notes": "Valuation based on earnings growth and EV/EBITDA multiples, with 12M target implying 39% upside. Not investment advice.", "current_price": 186.76, "recommendation": "STRONG_BUY", "thesis_bullets": [ "Strong historical EPS growth at 36.5% year-over-year.", "Low PEG ratio of 0.255 indicates potential undervaluation.", "Stable revenue growth in resilient healthcare sector.", "Opportunity for margin expansion with operational improvements.", "Balanced by regulatory risks and moderate debt levels." ], "target_price_6m": 220, "target_price_12m": 260 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 337, "createdAt": "2026-04-09T05:22:00.625Z", "usage": { "inputTokens": 2079, "outputTokens": 4530, "costUsd": 0.002485 } }, { "id": "cmnr15d8h06qvp658lsbyl89z", "runId": "cmnr15d8d06qsp658tbyv4abx", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"UHS_Equity_Model_v1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"UHS\",\n \"currency\": \"USD\",\n \"current_price\": 186.76,\n \"target_price_6m\": 210.00,\n \"target_price_12m\": 232.00,\n \"recommendation\": \"STRONG_BUY\",\n \"confidence\": 0.80,\n \"thesis_bullets\": [\n \"Valuation is highly compelling at 9.3x P/E despite 20% ROE and strong cash generation.\",\n \"Behavioral health segment benefits from secular demand tailwinds and improving pricing power.\",\n \"Acute care volumes are stabilizing, with higher acuity treatments driving revenue per adjusted admission.\",\n \"Contract labor costs are normalizing, providing a clear runway for operating margin expansion.\",\n \"Robust $809M FCF supports aggressive share repurchases and debt reduction, enhancing shareholder yield.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Behavioral Health Demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Contract Labor Costs\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Medicare/Medicaid Rates\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Acute Care Admissions\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Share Repurchases\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest Expense\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Adverse changes to Medicare or Medicaid reimbursement rates.\",\n \"Resurgence in nursing shortages driving up premium contract labor expenses.\",\n \"Regulatory scrutiny or litigation regarding behavioral health facility operations.\",\n \"High debt load ($5.5B) increases vulnerability to sustained high interest rates.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.055,\n \"ebit_margin_target\": 0.115,\n \"wacc\": 0.085,\n \"terminal_multiple\": 8.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 160.00,\n \"prob\": 0.15,\n \"notes\": \"Labor costs remain elevated and reimbursement rates fail to keep pace with inflation.\"\n },\n \"base\": {\n \"target_price\": 232.00,\n \"prob\": 0.60,\n \"notes\": \"Steady volume growth and normalizing labor costs drive margin expansion and multiple re-rating.\"\n },\n \"bull\": {\n \"target_price\": 275.00,\n \"prob\": 0.25,\n \"notes\": \"Strong behavioral health pricing and accretive capital deployment accelerate EPS growth.\"\n }\n },\n \"method_notes\": \"Valuation based on a DCF model and EV/EBITDA multiple expansion. The probability-weighted scenario return is >20%, supporting a STRONG_BUY recommendation. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "UHS_Equity_Model_v1", "risks": [ "Adverse changes to Medicare or Medicaid reimbursement rates.", "Resurgence in nursing shortages driving up premium contract labor expenses.", "Regulatory scrutiny or litigation regarding behavioral health facility operations.", "High debt load ($5.5B) increases vulnerability to sustained high interest rates." ], "ticker": "UHS", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady volume growth and normalizing labor costs drive margin expansion and multiple re-rating.", "target_price": 232 }, "bear": { "prob": 0.15, "notes": "Labor costs remain elevated and reimbursement rates fail to keep pace with inflation.", "target_price": 160 }, "bull": { "prob": 0.25, "notes": "Strong behavioral health pricing and accretive capital deployment accelerate EPS growth.", "target_price": 275 } }, "confidence": 0.8, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.055, "terminal_multiple": 8, "ebit_margin_target": 0.115 }, "key_drivers": [ { "driver": "Behavioral Health Demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Contract Labor Costs", "impact": "HIGH", "direction": "NEG" }, { "driver": "Medicare/Medicaid Rates", "impact": "HIGH", "direction": "NEG" }, { "driver": "Acute Care Admissions", "impact": "MED", "direction": "POS" }, { "driver": "Share Repurchases", "impact": "MED", "direction": "POS" }, { "driver": "Interest Expense", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on a DCF model and EV/EBITDA multiple expansion. The probability-weighted scenario return is >20%, supporting a STRONG_BUY recommendation. Not investment advice.", "current_price": 186.76, "recommendation": "STRONG_BUY", "thesis_bullets": [ "Valuation is highly compelling at 9.3x P/E despite 20% ROE and strong cash generation.", "Behavioral health segment benefits from secular demand tailwinds and improving pricing power.", "Acute care volumes are stabilizing, with higher acuity treatments driving revenue per adjusted admission.", "Contract labor costs are normalizing, providing a clear runway for operating margin expansion.", "Robust $809M FCF supports aggressive share repurchases and debt reduction, enhancing shareholder yield." ], "target_price_6m": 210, "target_price_12m": 232 }, "errorsJson": { "attempts": [ { "error": "sanity_error: ultra_buy_scenario_return_too_low: STRONG_BUY requires >= 20% return from probability-weighted scenarios.", "attempt": 0, "rawOutputTruncated": "{\n \"model\": \"UHS_Equity_Model_v1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"UHS\",\n \"currency\": \"USD\",\n \"current_price\": 186.76,\n \"target_price_6m\": 205.00,\n \"target_price_12m\": 225.00,\n \"recommendation\": \"STRONG_BUY\",\n \"confidence\": 0.80,\n \"thesis_bullets\": [\n \"Valuation is highly compelling at 9.3x P/E despite 20% ROE and strong cash generation.\",\n \"Behavioral health segment benefits from secular demand tailwinds and improving pricing power.\",\n \"Acute care volumes are stabilizing, with higher acuity treatments driving revenue per adjusted admission.\",\n \"Contract labor costs are normalizing, providing a clear runway for operating margin expansion.\",\n \"Robust $809M FCF supports aggressive share repurchases and debt reduction, enhancing shareholder yield.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Behavioral Health Demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Contract Labor Costs\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Medicare/Medicaid Rates\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Acute Care Admissions\",\n \"impact\": \"…" } ], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 24401, "createdAt": "2026-04-09T05:22:00.625Z", "usage": { "inputTokens": 3161, "outputTokens": 833, "costUsd": 0.016318 } }, { "id": "cmnr15d8h06qtp658uq4tu8b1", "runId": "cmnr15d8d06qsp658tbyv4abx", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"gpt-5\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"UHS\",\"currency\":\"USD\",\"current_price\":186.76,\"target_price_6m\":197,\"target_price_12m\":204,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"Behavioral health assets support steadier occupancy and pricing than acute-care peers.\",\"Low 9x earnings and ~7x EBITDA imply muted expectations already.\",\"Recent EPS growth and double-digit operating margin show improved execution.\",\"Leverage, thin liquidity, and reimbursement pressure cap multiple expansion.\",\"Risk-reward favors modest upside, but not enough for high-conviction call.\"],\"key_drivers\":[{\"driver\":\"Behavioral health demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Acute admissions and pricing\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Labor cost normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Government reimbursement rates\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Payer denials and bad debt\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Leverage and interest expense\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Margin discipline\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Capital allocation/buybacks\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Labor inflation reaccelerates.\",\"Medicare/Medicaid reimbursement weakens.\",\"Payer denials or bad debt rises.\",\"Behavioral health regulatory or litigation issues.\",\"Balance-sheet flexibility remains limited.\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.115,\"wacc\":0.085,\"terminal_multiple\":8},\"scenarios\":{\"bear\":{\"target_price\":165,\"prob\":0.25,\"notes\":\"Wage pressure and weak reimbursement keep multiples compressed.\"},\"base\":{\"target_price\":204,\"prob\":0.5,\"notes\":\"Moderate volume growth and stable margins support modest rerating.\"},\"bull\":{\"target_price\":228,\"prob\":0.25,\"notes\":\"Behavioral strength and labor normalization drive stronger EPS growth.\"}},\"method_notes\":\"Blended earnings-power view using snapshot fundamentals with normalized P/E and EV/EBITDA anchors; no sell-side price targets used. Snapshot quote fields kept authoritative. BUY reflects ~9% 12M upside with moderate uncertainty; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "gpt-5", "risks": [ "Labor inflation reaccelerates.", "Medicare/Medicaid reimbursement weakens.", "Payer denials or bad debt rises.", "Behavioral health regulatory or litigation issues.", "Balance-sheet flexibility remains limited." ], "ticker": "UHS", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate volume growth and stable margins support modest rerating.", "target_price": 204 }, "bear": { "prob": 0.25, "notes": "Wage pressure and weak reimbursement keep multiples compressed.", "target_price": 165 }, "bull": { "prob": 0.25, "notes": "Behavioral strength and labor normalization drive stronger EPS growth.", "target_price": 228 } }, "confidence": 0.64, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 8, "ebit_margin_target": 0.115 }, "key_drivers": [ { "driver": "Behavioral health demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Acute admissions and pricing", "impact": "MED", "direction": "POS" }, { "driver": "Labor cost normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Government reimbursement rates", "impact": "HIGH", "direction": "NEG" }, { "driver": "Payer denials and bad debt", "impact": "MED", "direction": "NEG" }, { "driver": "Leverage and interest expense", "impact": "MED", "direction": "NEG" }, { "driver": "Margin discipline", "impact": "MED", "direction": "POS" }, { "driver": "Capital allocation/buybacks", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended earnings-power view using snapshot fundamentals with normalized P/E and EV/EBITDA anchors; no sell-side price targets used. Snapshot quote fields kept authoritative. BUY reflects ~9% 12M upside with moderate uncertainty; not investment advice.", "current_price": 186.76, "recommendation": "BUY", "thesis_bullets": [ "Behavioral health assets support steadier occupancy and pricing than acute-care peers.", "Low 9x earnings and ~7x EBITDA imply muted expectations already.", "Recent EPS growth and double-digit operating margin show improved execution.", "Leverage, thin liquidity, and reimbursement pressure cap multiple expansion.", "Risk-reward favors modest upside, but not enough for high-conviction call." ], "target_price_6m": 197, "target_price_12m": 204 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_03190b27f8e817290069d75e45f2788196bfb3241b11e70851", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 31000, "createdAt": "2026-04-09T05:22:00.625Z", "usage": { "inputTokens": 2352, "outputTokens": 1467, "costUsd": 0.024654 } }, { "id": "cmnr15d8h06qwp658a6lvk9g3", "runId": "cmnr15d8d06qsp658tbyv4abx", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"UHS\",\n \"currency\": \"USD\",\n \"current_price\": 186.76,\n \"target_price_6m\": 205,\n \"target_price_12m\": 220,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Undervalued at 9.3x P/E with PEG of 0.25\",\n \"Strong 36% EPS growth and 10% revenue rise\",\n \"Demographics drive sustained hospital demand\",\n \"High debt levels heighten financial vulnerability\",\n \"Labor shortages may compress operating margins\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"EPS and revenue growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Aging population demand\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory reimbursement\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Labor cost inflation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"FCF funded debt paydown\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Valuation multiple expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Economic downturn risk\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operational efficiency gains\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Medicare/Medicaid reimbursement cuts\",\n \"Persistent healthcare labor shortages\",\n \"High leverage and interest burden\",\n \"Rise in uncompensated care\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.07,\n \"ebit_margin_target\": 0.12,\n \"wacc\": 0.085,\n \"terminal_multiple\": 9\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 165,\n \"prob\": 0.3,\n \"notes\": \"Regulatory cuts and margin pressure materialize.\"\n },\n \"base\": {\n \"target_price\": 220,\n \"prob\": 0.5,\n \"notes\": \"Steady growth and current margins continue.\"\n },\n \"bull\": {\n \"target_price\": 265,\n \"prob\": 0.2,\n \"notes\": \"Accelerated growth with multiple re-rating.\"\n }\n },\n \"method_notes\": \"3-stage DCF using revenue CAGR, target EBIT margin, 8.5% WACC and 9x terminal EV/EBITDA; 12M target implies 18% upside. Balanced bull/bear drivers support BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Valuation Model", "risks": [ "Medicare/Medicaid reimbursement cuts", "Persistent healthcare labor shortages", "High leverage and interest burden", "Rise in uncompensated care" ], "ticker": "UHS", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady growth and current margins continue.", "target_price": 220 }, "bear": { "prob": 0.3, "notes": "Regulatory cuts and margin pressure materialize.", "target_price": 165 }, "bull": { "prob": 0.2, "notes": "Accelerated growth with multiple re-rating.", "target_price": 265 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.07, "terminal_multiple": 9, "ebit_margin_target": 0.12 }, "key_drivers": [ { "driver": "EPS and revenue growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Aging population demand", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory reimbursement", "impact": "HIGH", "direction": "NEG" }, { "driver": "Labor cost inflation", "impact": "HIGH", "direction": "NEG" }, { "driver": "FCF funded debt paydown", "impact": "MED", "direction": "POS" }, { "driver": "Valuation multiple expansion", "impact": "MED", "direction": "POS" }, { "driver": "Economic downturn risk", "impact": "LOW", "direction": "NEG" }, { "driver": "Operational efficiency gains", "impact": "MED", "direction": "POS" } ], "method_notes": "3-stage DCF using revenue CAGR, target EBIT margin, 8.5% WACC and 9x terminal EV/EBITDA; 12M target implies 18% upside. Balanced bull/bear drivers support BUY. Not investment advice.", "current_price": 186.76, "recommendation": "BUY", "thesis_bullets": [ "Undervalued at 9.3x P/E with PEG of 0.25", "Strong 36% EPS growth and 10% revenue rise", "Demographics drive sustained hospital demand", "High debt levels heighten financial vulnerability", "Labor shortages may compress operating margins" ], "target_price_6m": 205, "target_price_12m": 220 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "03d2c307-67cd-983e-8a60-b5d4ba2f9201", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 15515, "createdAt": "2026-04-09T05:22:00.625Z", "usage": { "inputTokens": 2691, "outputTokens": 2879, "costUsd": 0.051258 } } ] } }